Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ERI-0206
- Development stage
- Preclinical
- Lead developer
- Factor Bioscience
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ERI-0206 is a preclinical-stage chimeric antigen receptor (CAR) T-cell therapy developed by Novatium in collaboration with Factor Bioscience. This therapy is engineered to dual-target the CD5 and CD52 antigens, which are associated with renal cell carcinoma (RCC). The dual-targeting strategy is intended to enhance the specificity and potency of the T-cell response against solid tumors, potentially reducing the risk of antigen escape. The program utilizes Factor Bioscience's cell-engineering technologies to create a targeted immunotherapy for patients with renal cell carcinoma.
- Other names
- Novatium CD5-CD52 CAR-T cell therapy
02
Targets
Beyond the preview
Go deeper on ERI-0206.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERI-0206.